Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Boill Healthcare Holdings Limited
保集健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1246)

UPDATE ON JUDICIAL REVIEW

This announcement is made by Boill Healthcare Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the "**Listing Rules**") of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to (i) the announcement of the Company dated 25 July 2024 in relation to suspension of trading of the shares of the Company (the "**Shares**"); (ii) the announcements of the Stock Exchange dated 9 August 2024, 3 December 2024 and 13 February 2025 regarding the Company, which set out, among others, the resumption guidance for the resumption of trading in the Company's securities (the "**Resumption Guidance**"); (iii) the announcements of the Company dated 16 January 2026 and 25 January 2026 in relation to, among others, the progress in fulfilling the Resumption Guidance; (iv) the announcement of the Company dated 27 February 2026 in relation to the request for review of the decision of the listing committee; and (v) the announcement of the Company dated 21 May 2026 in relation to decision of listing review committee and judicial review (collectively, the "**Announcements**"). Unless otherwise specified, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

UPDATE ON JUDICIAL REVIEW

On 3 June 2026:

(a) the Company filed the Leave Application to the High Court to quash the LRC Decision and other remedy, relief and order as the High Court may provide; and

(b) the Company notified the Stock Exchange of the Judicial Review Proceedings and the grounds for judicial review.

Further announcement regarding any material development of the Judicial Review Proceedings and the implementation of the LRC Decision as and when appropriate and in accordance with the Listing Rules.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange was suspended at the request of the Company with effect from 9:31 a.m. on 25 July 2024.

Shareholders and potential investors of the Company should note that the intended application to judicial review does not mean the Company will not be delisted. The High Court may or may not grant leave for the judicial review and even if leave is granted, the judicial review may or may not succeed. Shareholders and potential investors of the Company who have any queries about the implications of the cancellation of listing of the Shares are advised to obtain appropriate professional advice.

By order of the Board
Boill Healthcare Holdings Limited
Zhuo Wenjie
Executive Director and Chairman

Hong Kong, 5 June 2026

As at the date of this announcement and after the above appointments and resignations, the Company has (i) three executive Directors, namely Mr. Zhuo Wenjie, Mr. Yu Sicheng and Mr. Chen Wei; (ii) one non-executive Director, namely Dr. Tang Sing Hing, Kenny; and (iii) three independent non-executive Directors, namely Mr. Yau Yan Yuen, Ms. Xiao Lihong and Mr. Liang Yanan.